News
DCPH
--
0.00%
--
Blueprint Medicines Reports Positive Test Results For Rare Disease Treatment; BPMC Stock Jumps
Investor's Business Daily · 09/22 15:50
An Intrinsic Calculation For Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Suggests It's 48% Undervalued
How far off is Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) from its intrinsic value? Using the most recent financial...
Simply Wall St. · 09/20 14:12
Deciphera Pharma's QINLOCK shows sustained benefit in gastrointestinal tumor
Deciphera Pharmaceuticals (DCPH) has announced nine month follow-up data from the Company’s Phase 3 INVICTUS study of QINLOCK in patients with fourth-line and fourth-line plus gastrointestinal stromal tumors ((GIST)) and
Seekingalpha · 09/18 12:02
Deciphera Presents Data from QINLOCK (Ripretinib) Program in Patients with Gastrointestinal Stromal Tumor at the European Society for Medical Oncology (ESMO) Virtual Congress 2020
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), today announced the presentation of nine month follow-up data from the Company’s Phase 3 INVICTUS study of QINLOCK in patients with fourth-line and fourth-line plus gastrointestinal stromal tumors (GIST) and intra-patient dose escalation data from the ongoing
Business Wire · 09/18 12:00
Deciphera Pharma Reports Will Present 9-Month Follow-Up Data From Phase 3 INVICTUS Study Of QINLOCK In Patients With Fourth-Line Gastrointestinal Stromal Tumors At European Society For Medical Oncology Meeting Sept. 19-21
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), today announced the presentation of nine month follow-up data from the Company’s Phase 3 INVICTUS study of QINLOCK in patients with fourth-line and fourth-line plus
Benzinga · 09/18 11:04
Deciphera's rebastinib shows encouraging efficacy in ovarian cancer
Deciphera Pharmaceuticals (DCPH) announces data from the ovarian cancer cohort in Part 2 of the ongoing Phase 1b/2 study of rebastinib, the selective TIE2 inhibitor, in combination with paclitaxel and
Seekingalpha · 09/17 11:51
Deciphera Presents Data from Rebastinib Its TIE2 Inhibitor Program At the European Society for Medical Oncology (ESMO) Virtual Congress 2020
- Rebastinib Combined with Paclitaxel Showed Encouraging Preliminary Clinical Benefit and Favorable Tolerability in Patients with Platinum-resistant Ovarian Cancer -  - Rebastinib Combined with Carboplatin was
Rebastinib Combined with Paclitaxel Showed Encouraging Preliminary Clinical Benefit and Favorable Tolerability in Patients with Platinum-resistant Ovarian Cancer -  - Rebastinib Combined with Carboplatin was · 09/17 11:04
Hedge Funds Never Been This Bullish On Deciphera Pharmaceuticals, Inc. (DCPH)
The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 823 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F filings show the funds' and investors' portfolio positions as of June 30th, when the S&P 500 Index
Insider Monkey · 09/15 05:48
The Week Ahead In Biotech: Decision Day For Bausch Health, IPO Flow Resumes, Oncology Conference
Biotech stocks continued to remain under pressure in the week ended Sept. 11, swayed by the volatility that was evident in the broader market.
Benzinga · 09/13 13:49
Deciphera Announces Publication of QINLOCK (ripretinib) Phase 1 Study Results in Patients with Gastrointestinal Stromal Tumor in Journal of Clinical Oncology
Business Wire · 08/17 21:30
Deciphera Announces The Publication Of QINLOCK Phase 1 Study Results In Patients With Gastrointestinal Stromal Tumor In Journal O Clinical Oncology
-  Results Consistent with Those Presented at the 2019 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics and Support Ongoing INTRIGUE Phase 3 Clinical Study in Patients with
 Results Consistent with Those Presented at the 2019 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics and Support Ongoing INTRIGUE Phase 3 Clinical Study in Patients with · 08/17 20:34
Week In Review: BioKangtai Acquires China Rights To AstraZeneca's COVID-19 Vaccine
BioKangtai, a Guangdong vaccine company, in-licensed rights to develop, manufacture and market AstraZeneca's COVID-19 vaccine in China.Biogen announced a $2 billion blockbuster deal to partner Denali Therapeutics' potential Parkinson's Disease therapy.Nanjing Simcere Pharma in-licensed Greater China rights to trilaciclib from North Carolina's GI Therapeutics in a $170 million agreement.
Seekingalpha · 08/09 20:02
Week In Review: BioKangtai Acquires China Rights To AstraZeneca's COVID-19 Vaccine
Seeking Alpha - Article · 08/09 20:02
Deciphera Pharmaceuticals, Inc. to Present at the Canaccord Genuity 40th Annual Growth Conference
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), today announced that Steve Hoerter, President and Chief Executive Officer, will present at the Canaccord Genuity 40th Annual Growth Conference on Thursday, August 13, 2020 at 9:00 AM ET. The conference will be hel
Business Wire · 08/06 12:40
Deciphera Pharmaceuticals EPS beats by $0.17, beats on revenue
Deciphera Pharmaceuticals (NASDAQ:DCPH): Q2 GAAP EPS of -$1.20 beats by $0.17. Revenue of $4.83M beats by $3.84M. Press Release
seekingalpha · 08/05 01:26
Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q2 Loss, Tops Revenue Estimates
Deciphera Pharmaceuticals, Inc. (DCPH) delivered earnings and revenue surprises of 10.45% and 249.26%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 08/04 22:25
Deciphera Pharmaceuticals Entered Into An Open Market Sale Agreement With Jefferies; May Issue And Sell Shares Of Common Stock Having Aggregate Offering Sales Proceeds Of Up To $200M From Time To Time
-Reuters
Reuters · 08/04 21:17
Deciphera Pharmaceuticals Q2 EPS $(1.20) Beats $(1.37) Estimate, Sales $7.10M Beat $900.00K Estimate
Deciphera Pharmaceuticals (NASDAQ:DCPH) reported quarterly losses of $(1.20) per share which beat the analyst consensus estimate of $(1.37) by 12.41 percent. This is a 114.29 percent decrease over losses of $(0.56) per
Benzinga · 08/04 20:22
Deciphera Pharmaceuticals, Inc. Announces Second Quarter 2020 Financial Results
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced financial results for the second quarter ended June 30, 2020 and provided an update on clinical and corporate developments.
Business Wire · 08/04 20:05
Deciphera Pharmaceuticals, Inc. to Announce Second Quarter 2020 Financial Results and Host Conference Call and Webcast on August 4, 2020
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced that it will report its second quarter 2020 financial results on Tuesday, August 4, 2020.
Business Wire · 07/29 11:00
Webull provides a variety of real-time DCPH stock news. You can receive the latest news about Deciphera Pharms through multiple platforms. This information may help you make smarter investment decisions.
About DCPH
Deciphera Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing drugs to improve the lives of cancer patients. Its drug candidate includes DCC-2618, DCC-3014 and Rebastinib. Its proprietary kinase switch control inhibitor platform, inhibit the activation of kinases. DCC-2618, an orally administered kinase switch control inhibitor, for the treatment of gastrointestinal stromal tumors (GIST), advanced systemic mastocytosis (ASM), gliomas, including glioblastoma multiforme (GBM), and other solid tumors driven by pan-KIT or PDGFR alpha. DCC-3014 is an orally administered, potent and highly selective inhibitor of colony stimulating factor receptor 1 (CSF1R). Rebastinib is an orally administered, potent and selective inhibitor of the TIE2 immunokinase. Rebastinib binds potently into the switch pocket of TIE2, stabilizing the inhibitory switch and displacing the activation switch to block TIE2 signaling.
More